Seaport Therapeutics, Inc. IPO - What You Need to Know

Thinking about the Seaport Therapeutics IPO? Getting in on the ground floor of a biotech company is exciting, but these investments can be a rollercoaster. Here is a plain-English breakdown of what you need to know before you decide to invest.

1. What does this company do?

Seaport is a clinical-stage biotech company focused on treating depression and anxiety. Their "secret sauce" is a technology platform called Glyph.

The body’s lymphatic system usually filters out many drugs before they reach the brain. Seaport attaches a lipid-based molecule to their drugs, allowing them to bypass the liver and travel directly through the lymphatic system. This helps more medication reach the brain while potentially lowering side effects. They are applying this technology to existing, proven drugs to make them work better.

2. What are their main projects?

• GlyphAllo (SPT-300): Their lead product treats depression and anxiety. They expect results from their Phase 2b clinical trial by early 2027.
• GlyphAgo (SPT-320): This drug treats anxiety. In early studies, it showed much better absorption into the body than the original version of the drug.
• Glyph2BLSD (SPT-348): An early-stage program for depression and PTSD. It uses the Glyph platform to deliver a non-hallucinogenic version of a psychedelic compound.

3. How do they make money?

Seaport makes no money yet. They have no product sales and do not expect any for the foreseeable future. They currently lose money while funding research and clinical trials. In 2025, they reported a loss of $74.9 million.

4. What will they do with the IPO money?

Seaport is selling 14,160,000 shares at $18.00 each. They expect to raise about $234 million. They will use this cash to fund clinical trials for SPT-300 and SPT-320, continue research on SPT-348, and cover general business costs. They believe this money will fund operations into 2029, though this depends on how fast their trials move.

5. Who’s running the show?

The leadership team has deep experience in neuroscience. The co-founders helped build Karuna Therapeutics, which created a successful schizophrenia treatment and was later bought for $14 billion. While this team has a strong track record, past success does not guarantee that Seaport’s current drugs will win regulatory approval.

6. What are the main risks?

• The "All-or-Nothing" Gamble: The company’s value rests on a very small number of projects. If their main trials fail, the company’s future is at risk.
• The "FDA Hurdle": Getting a drug approved is difficult. The FDA may demand more studies or reject the drugs entirely. Delays in patient sign-ups or safety concerns could stall or kill these programs.
• The "Dilution" Risk: Because they have no revenue, Seaport will likely need more cash later. They will likely issue more shares to raise money, which reduces your ownership percentage.
• A History of Losses: The company has lost $114.1 million to date. Expenses will only grow as they run more clinical trials.

7. Ticker and Trading

Seaport will trade on the Nasdaq under the ticker symbol "SPTX."

Final Thoughts for Investors

Before you buy, ask yourself if you are comfortable with the "biotech bet." You are essentially investing in the success of the Glyph platform and the clinical trial outcomes for SPT-300 and SPT-320. If you believe in the team's ability to replicate their past success, this might be on your radar—but remember that the path to FDA approval is long, expensive, and uncertain.

Disclaimer: I am an AI, not a financial advisor. Biotech IPOs are volatile and you could lose your entire investment. Never invest money you cannot afford to lose, and read the company’s official "S-1" filing on the SEC website before making any final decisions.